METHODS: Patients with HER2-negative, non-metastatic, breast cancer received scalp cooling during adjuvant chemotherapy: three cycles of epirubicin/cyclophosphamide (EC) followed by three cycles of paclitaxel. The patients were randomly assigned to two groups. Group A (n=18) wore a Paxman cooling cap during each infusion and for 30 min post-infusion while Group B (n=19) wore the cap from 30 min before to 2 h after each infusion. All patients were asked to complete a questionnaire recording hair loss/regrowth, adverse events, and quality of life. Success of treatment was defined as <50% hair loss.
RESULTS: The success rates after each of the three cycles did not differ significantly between the two groups (EC: Group A: 40%, Group B: 44%; paclitaxel: Group A: 50%, Group B: 36%; p>0.05). Hair regrowth was significantly higher in Group B at the 8-week follow-up, but not at the 6-month follow-up. Head discomfort affected more patients in Group B than in Group A during the first session (94% vs. 62%, respectively; p=0.039).
CONCLUSIONS: Long duration scalp cooling during chemotherapy might increase patients\' discomfort and does not appear to improve hair preservation.
方法:HER2阴性患者,非转移性,乳腺癌在辅助化疗期间接受头皮冷却:3个周期的表柔比星/环磷酰胺(EC),随后3个周期的紫杉醇.将患者随机分为两组。A组(n=18)在每次输注期间和输注后30分钟戴Paxman冷却帽,而B组(n=19)在每次输注前30分钟至2小时戴帽。要求所有患者完成记录脱发/再生的问卷,不良事件,和生活质量。治疗成功定义为<50%脱发。
结果:三个周期中每个周期后的成功率在两组之间没有显着差异(EC:A组:40%,B组:44%;紫杉醇:A组:50%,B组:36%;p>0.05)。在8周的随访中,B组的头发再生明显更高,但不是在6个月的随访中。在第一次会议期间,B组的头部不适影响的患者多于A组(94%与62%,分别为;p=0.039)。
结论:化疗期间长时间的头皮冷却可能会增加患者的不适感,并且似乎不会改善头发保存。